Inclusion-Body Myositis Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Intravenous immunoglobulin in the treatment of sporadic inclusion body myositis: time for new evidence?
Clin Exp Rheumatol. 2024 Feb 19. doi: 10.55563/clinexprheumatol/7x5o3q. Online ahead of print.NO ABSTRACTPMID:38372729 | DOI:10.55563/clinexprheumatol/7x5o3q (Source: Clinical and Experimental Rheumatology)
Source: Clinical and Experimental Rheumatology - February 19, 2024 Category: Rheumatology Authors: Lorenzo Fontanelli Gabriele Vadi Erika Schirinzi Giulia Di Rauso Gabriele Bellini Giulia Ricci Gabriele Siciliano Source Type: research

Imaging swallowing function and the mechanisms driving dysphagia in inclusion body myositis
Clin Exp Rheumatol. 2024 Feb 16. doi: 10.55563/clinexprheumatol/t1x3qa. Online ahead of print.ABSTRACTSporadic inclusion body myositis (IBM) is a progressive condition which commonly affects patients aged above 40. IBM does not respond to immunosuppression and no proven treatments are available. Up to 80% of patients develop some degree of swallowing impairment during the disease course. Dysphagia is a source of marked morbidity in IBM and predisposes patients to life-threatening complications such as aspiration pneumonia. The pathophysiology behind dysphagia in IBM is not fully understood. Evidence from imaging demonstrat...
Source: Clinical and Experimental Rheumatology - February 19, 2024 Category: Rheumatology Authors: Sharfaraz Salam Jodi Allen Mazen M Dimachkie Michael G Hanna Pedro M Machado Source Type: research

Cancer risk and mortality in hospitalised patients with idiopathic inflammatory myopathies in Western Australia
CONCLUSION: Cancer risk is not increased prior to IIM, but CIR for lung cancer is increased following DM diagnosis. As cancer reduced survival only in DM and IBM patients, these data support a strategy of limited cancer screening in IIM.PMID:38302176 | DOI:10.3899/jrheum.2023-1044 (Source: J Rheumatol)
Source: J Rheumatol - February 1, 2024 Category: Rheumatology Authors: Johannes Nossent Helen Keen David Preen Charles Inderjeeth Source Type: research

Cancer risk and mortality in hospitalised patients with idiopathic inflammatory myopathies in Western Australia
CONCLUSION: Cancer risk is not increased prior to IIM, but CIR for lung cancer is increased following DM diagnosis. As cancer reduced survival only in DM and IBM patients, these data support a strategy of limited cancer screening in IIM.PMID:38302176 | DOI:10.3899/jrheum.2023-1044 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - February 1, 2024 Category: Rheumatology Authors: Johannes Nossent Helen Keen David Preen Charles Inderjeeth Source Type: research